Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
Status:
Unknown status
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Central serous chorioretinopathy (CSC) has been known since it was first described by Von
Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized
disorder leading to serous neurosensory elevation of the central macula. The acute form of
the disease is associated with focal leakage at the level of the retinal pigment epithelium
(RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the
majority of patients, who also regain excellent vision. Occasionally, the neurosensory
detachment persists and leads to pigment epithelial and photoreceptor damage with visual
impairment.
The purpose of this clinical study is report the use of intravitreal bevacizumab is a new
option in the treatment of the chronic or recurrent CSC.